Pilot & Feasibility
Protocols & Methods
Reagents & Resources
Tissues & Samples
IMPC / KOMP Data
Pilot & Feasibility
Impact of Diabetes on Renal Transporters in Females and Males
PROJECT SUMMARY (See instructions): The diabetes complication addressed in this DiaComp pilot proposal is diabetic nephropathy (DN). 25% of people in US are obese and another 35% are overweight. 10% of the people in US have diabetes. 32% of people in US have hypertension. 1 in 10 Americans have chronic kidney disease. 500,000 people are on dialysis at a cost to Medicare exceeding $ 40 billion. These issues are closely interrelated as diabetes raises blood pressure and hypertension provokes insulin resistance. Additionally, the kidney contains the blood pressure set point as well as key therapeutic targets for diabetes (inhibitors of renin angiotensin system and SGLT2). Significant sex disparities are evident in the incidence and treatment outcomes of DN in humans as well as rodent models of DN. The broad long-term objective of this proposal is to define sexual dimorphisms in the renal tubular responses to type 2 diabetes (T2D) as a basis for optimizing sex specific therapies. We recently reported the sexual dimorphic profile of renal transporters and channels as well as the impact on electrolyte homeostasis in normal baseline Sprague Dawley rats and C57Bl/6J mice. Notably, females exhibited lower proximal transport (less NHE3 activation, less NaPi2), coupled to higher distal sodium reabsorption (more NCC, ENaC activation) facilitating more rapid excretion of a saline challenge as well as lowers plasma K+ set point. Our modelling of the female vs male proximal tubule revealed the necessity for higher Na+-glucose transporter (SGLT2) abundance in females vs. males to reabsorb the filtered load, reported experimentally. The ability to detect renal transporters sloughed into the tubule fluid and urine in exosomes provides a set of biomarkers for transporter activation along the nephron at baseline and during diabetes that can be verified in rodents and applied to humans. We propose to: Aim 1. Determine the impact of T2D in both males and females in two accepted and widely studied models of DN: 1) obese (vs. lean) ZSF1 rats, 2) db/db (vs db/m) C57BL/6J mice. Provide transporter profiles (abundance covalent modification and distribution) of renal Na+, K+, HCO3-, glucose, organic acid transporters, claudins, water and K+ channels and associated regulators. Assess physiologic and hemodynamic impact by measuring urine and plasma responses, blood pressure and GFR. Aim 2. Implement protocols to assess transporter activation by phosphorylation or cleavage in urine exosomes collected overnight in ZSF1 rats and in a set of urines on hand from Nephrology clinic (both M and F). Assess NHE3-P/ NHE3, NKCC-P/NKCC, NCC-P/NCC, and ENaCg full length/cleaved. RELEVANCE (See instructions): According to World Health Organization, Chronic Kidney Disease (CKD) is the 12th leading cause of death, 17th leading cause of disability in the world. More than 40% of CKD is due to type 2 diabetes (T2D). In the US, more than 500,000 people are on dialysis at a cost to Medicare exceeding $40 billion/yr. There are significant sex disparities in the epidemiology and outcomes of CKD. We aim to define renal tubular responses to T2D in females vs. male rodent models and in urinary biomarkers in both rodents and humans.
No funding program application progress reports found.
No uploaded documents found.
No publications found.
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Nephropathy Committee has the principal function of furthering the mission of the consortium with regard to diabetic kidney disease.
Curation Flag Information
New comment to be added:
No experiments found.
No strains found.
No models found.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!